Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

Summary

Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.

Conditions

• Healthy Volunteer
• Prostate Cancer
• Head and Neck Cancer
• Esophageal Cancer
• Genitourinary Cancer
• Sarcoma
• Breast Cancer
• Colon Cancer
• Gastrointestinal Cancer
• Solid Tumor Cancer
• Lung Cancer
• Skin Cancer
• Melanoma

Sponsors & Collaborators

• Roche Sequencing Solutions

  collaborator INDUSTRY

• The Foundation for Barnes-Jewish Hospital

  collaborator OTHER

• National Center for Advancing Translational Sciences (NCATS)

  collaborator NIH

• Radiological Society of North America

  collaborator OTHER

• Skandalaris

  collaborator UNKNOWN

• The V Foundation for Cancer Research

  collaborator OTHER

• National Institute of General Medical Sciences (NIGMS)

  collaborator NIH

• Washington University School of Medicine

  lead OTHER

Principal Investigators

• Melissa Reimers, M.D. · Washington University School of Medicine

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2019-05-29

Primary Completion

2026-12-31

Completion

2026-12-31

Countries

• United States

Study Locations